CL2012002551A1 - Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. - Google Patents

Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.

Info

Publication number
CL2012002551A1
CL2012002551A1 CL2012002551A CL2012002551A CL2012002551A1 CL 2012002551 A1 CL2012002551 A1 CL 2012002551A1 CL 2012002551 A CL2012002551 A CL 2012002551A CL 2012002551 A CL2012002551 A CL 2012002551A CL 2012002551 A1 CL2012002551 A1 CL 2012002551A1
Authority
CL
Chile
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
CL2012002551A
Other languages
English (en)
Spanish (es)
Inventor
Klaus Schiene
Funke Petra Bloms
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of CL2012002551A1 publication Critical patent/CL2012002551A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2012002551A 2010-06-15 2012-09-14 Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. CL2012002551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15

Publications (1)

Publication Number Publication Date
CL2012002551A1 true CL2012002551A1 (es) 2012-11-09

Family

ID=42395008

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002551A CL2012002551A1 (es) 2010-06-15 2012-09-14 Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.

Country Status (29)

Country Link
US (3) US8846765B2 (https=)
EP (2) EP2992877A1 (https=)
JP (3) JP6133772B2 (https=)
KR (1) KR101831616B1 (https=)
CN (1) CN103108631B (https=)
AR (1) AR081931A1 (https=)
AU (2) AU2011267474B2 (https=)
BR (1) BR112012031836A2 (https=)
CA (1) CA2796774C (https=)
CL (1) CL2012002551A1 (https=)
CO (1) CO6602157A2 (https=)
CY (1) CY1117118T1 (https=)
DK (1) DK2582366T3 (https=)
EC (2) ECSP12012217A (https=)
ES (1) ES2560676T3 (https=)
HK (1) HK1215787A1 (https=)
HR (1) HRP20151327T1 (https=)
HU (1) HUE026619T2 (https=)
IL (1) IL221926A (https=)
MX (1) MX2012014482A (https=)
NZ (1) NZ602625A (https=)
PE (2) PE20130243A1 (https=)
PL (1) PL2582366T3 (https=)
PT (1) PT2582366E (https=)
RS (1) RS54439B1 (https=)
RU (2) RU2589692C2 (https=)
SI (1) SI2582366T1 (https=)
WO (1) WO2011157391A1 (https=)
ZA (1) ZA201208646B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2992877A1 (en) * 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PT3598971T (pt) 2013-01-22 2024-06-20 Vistagen Therapeutics Inc ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
KR20170013890A (ko) * 2014-05-06 2017-02-07 노쓰웨스턴유니버시티 Nmdar 조절 화합물의 조합물
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
JP7532718B2 (ja) * 2018-04-12 2024-08-14 アナベックス ライフ サイエンス コーポレイション 物質のａ２－７３結晶多形組成物およびそれらの使用方法
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
BR9912827A (pt) 1998-07-16 2001-05-02 Sloan Kettering Inst Cancer Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
WO2004022002A2 (en) 2002-09-09 2004-03-18 Endo Pharmaceuticals Inc. Combined immediate release and extended release analgesic composition
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
PL2012764T3 (pl) 2006-04-28 2011-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
JP2009539792A (ja) * 2006-06-08 2009-11-19 シュヴァルツ・ファーマ・アーゲー 疼痛の医学的状態のための治療組合せ
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
RS55769B1 (sr) * 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
EP2250148B1 (en) * 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
EP2992877A1 (en) * 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
ES2566828T3 (es) 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
CN103501775A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
KR102082529B1 (ko) 2012-04-17 2020-02-27 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법

Also Published As

Publication number Publication date
US20110306674A1 (en) 2011-12-15
US20170333369A1 (en) 2017-11-23
RU2675261C2 (ru) 2018-12-18
WO2011157391A1 (en) 2011-12-22
CA2796774A1 (en) 2011-12-22
AU2016219643A1 (en) 2016-09-15
HK1215787A1 (en) 2016-09-15
HK1184370A1 (zh) 2014-01-24
SI2582366T1 (sl) 2016-02-29
KR101831616B1 (ko) 2018-04-04
NZ602625A (en) 2014-03-28
JP6133772B2 (ja) 2017-05-24
PT2582366E (pt) 2016-01-26
US8846765B2 (en) 2014-09-30
JP6423036B2 (ja) 2018-11-14
JP2015232015A (ja) 2015-12-24
CO6602157A2 (es) 2013-01-18
US10813890B2 (en) 2020-10-27
CA2796774C (en) 2020-06-02
MX2012014482A (es) 2013-02-21
JP2013528629A (ja) 2013-07-11
AU2016219643B2 (en) 2018-04-12
RU2016119041A (ru) 2017-11-20
RU2589692C2 (ru) 2016-07-10
EP2582366B1 (en) 2015-10-28
AU2011267474B2 (en) 2016-05-26
DK2582366T3 (en) 2015-12-07
EP2582366A1 (en) 2013-04-24
ZA201208646B (en) 2013-09-25
ES2560676T3 (es) 2016-02-22
ECSP19047259A (es) 2019-07-31
US20140309311A1 (en) 2014-10-16
AR081931A1 (es) 2012-10-31
HUE026619T2 (en) 2016-06-28
AU2011267474A1 (en) 2013-01-10
CN103108631B (zh) 2015-08-26
PL2582366T3 (pl) 2016-04-29
RS54439B1 (sr) 2016-06-30
CN103108631A (zh) 2013-05-15
HRP20151327T1 (hr) 2016-01-01
JP2017141277A (ja) 2017-08-17
BR112012031836A2 (pt) 2016-11-08
RU2013101515A (ru) 2014-07-20
JP6197007B2 (ja) 2017-09-13
PE20160531A1 (es) 2016-06-05
IL221926A (en) 2015-08-31
ECSP12012217A (es) 2012-11-30
EP2992877A1 (en) 2016-03-09
PE20130243A1 (es) 2013-03-22
KR20130111945A (ko) 2013-10-11
CY1117118T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CR20150326A (es) Inhibidores de autotaxina
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
DOP2012000006A (es) Agonista de gpr119
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
UY32464A (es) Nuevos compuestos de indazol
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides